April 20, 2012

Genzyme Demonstrates Depth of MS Pipeline at AAN with Results from Multiple Sclerosis Phase lll Trials

- Full CARE-MS II Results for Alemtuzumab to Be Unveiled -

 

Genzyme Demonstrates Depth of MS Pipeline at AAN with Results from Multiple Sclerosis Phase lll Trials
- Full CARE-MS II Results for Alemtuzumab to Be Unveiled -

Paris, France – April 20, 2012 – Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced today that 12 data presentations, including six platform presentations, from the company’s multiple sclerosis (MS) clinical trial programs for alemtuzumab and teriflunomide will be featured at the American Academy of Neurology’s (AAN) 64th Annual Meeting in New Orleans, La., April 21-28. Presentations will include full data results from CARE-MS II (The Comparison of alemtuzumab and Rebif® Efficacy in Multiple Sclerosis), a Phase III trial investigating alemtuzumab in MS patients who had relapsed while receiving prior MS therapy, as well as new findings from the teriflunomide clinical program, one of the largest and broadest of any MS therapy in development.